Format

Send to

Choose Destination
Hepatology. 2007 Jul;46(1):254-65.

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.

Author information

1
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109-0362, USA. aslok@umich.edu

Abstract

Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy.

PMID:
17596850
DOI:
10.1002/hep.21698
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley Icon for MLibrary (Deep Blue)
Loading ...
Support Center